Spyre Therapeutics (SYRE) News Today $15.20 -0.13 (-0.82%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period BTIG Research Reaffirms "Buy" Rating for Spyre Therapeutics (NASDAQ:SYRE)September 18 at 2:25 AM | americanbankingnews.comBTIG Research Reaffirms Buy Rating for Spyre Therapeutics (NASDAQ:SYRE)September 17 at 8:11 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.6% - Should You Sell?September 16 at 7:33 PM | marketbeat.comLeerink Partners Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)September 16 at 11:37 AM | theglobeandmail.comSpyre Flat on Test ResultSeptember 15, 2025 | baystreet.caSpyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 TrialSeptember 15, 2025 | finance.yahoo.comSpyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic DiseasesSeptember 15, 2025 | markets.businessinsider.comWoodline Partners LP Grows Position in Spyre Therapeutics, Inc. $SYRESeptember 14, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Reduces Holdings in Spyre Therapeutics, Inc. $SYRESeptember 9, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street ZenSeptember 9, 2025 | marketbeat.comSpyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 8, 2025 | globenewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by BrokeragesSeptember 7, 2025 | marketbeat.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 18,428 Shares of StockSeptember 5, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsSeptember 5, 2025 | globenewswire.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $299,639.28 in StockSeptember 4, 2025 | insidertrades.comParadigm Biocapital Advisors LP Buys 600,000 Shares of Spyre Therapeutics, Inc. $SYRESeptember 2, 2025 | marketbeat.comNuveen LLC Makes New Investment in Spyre Therapeutics, Inc. $SYRESeptember 1, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street ZenSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 86,343 Shares of Spyre Therapeutics, Inc. $SYREAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Decreases Holdings in Spyre Therapeutics, Inc. $SYREAugust 28, 2025 | marketbeat.comVanguard Group Inc. Buys 51,794 Shares of Spyre Therapeutics, Inc. $SYREAugust 28, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to "Hold" RatingAugust 25, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5% - Here's WhyAugust 15, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 12, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 9, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from WedbushAugust 7, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPSAugust 6, 2025 | marketbeat.comSpyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 5, 2025 | globenewswire.comTD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 5, 2025 | marketbeat.comJefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 2, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsAugust 1, 2025 | globenewswire.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comVictory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)July 28, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsJuly 17, 2025 | marketbeat.comHere's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn SituationJuly 16, 2025 | finance.yahoo.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?July 15, 2025 | marketbeat.comSYRE - Spyre Therapeutics Inc Trailing Returns - MorningstarJuly 4, 2025 | morningstar.comMSpyre Therapeutics Announces Grants of Inducement AwardsJuly 3, 2025 | globenewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from AnalystsJune 22, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)June 20, 2025 | theglobeandmail.comSpyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardJune 18, 2025 | seekingalpha.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 7.7% - Here's WhyJune 17, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...June 17, 2025 | finanznachrichten.deSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 ReadoutsJune 17, 2025 | prnewswire.comSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025June 16, 2025 | prnewswire.comBank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 16, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.5% - Time to Buy?June 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 10, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsJune 6, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - Here's What HappenedJune 4, 2025 | marketbeat.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.350.72▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼94▲SYRE Articles Average Week Get the Latest News and Ratings for SYRE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ACLX News Today ADMA News Today ARWR News Today MENS News Today MIRM News Today MLTX News Today MTSR News Today PTGX News Today AAPG News Today LNTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts